

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”).

The board (“**Board**”) of directors (“**Directors**”) of Essex Bio-Technology Limited (“**Company**”, together with its subsidiaries, the “**Group**”) announces that on 11 November 2016, the Company has granted to three eligible persons (“**Grantees**”), subject to acceptance by such Grantees, share options (“**Share Options**”) to subscribe for up to 2,300,000 ordinary shares of HK\$0.1 each in the share capital of the Company (each, a “**Share**”) under the share option scheme adopted by the Company on 3 May 2013. Payment of HK\$1.00 will be made by each of the Grantees upon acceptance of the Share Options.

Details of the Options are set out below pursuant to Rule 17.06A of the Listing Rules:

| | | |
|---|---|---|
| Date of grant | : | 11 November 2016 (“ Date of Grant ”) |
| Exercise price of the Share Options granted | : | HK\$5.90 per Share (not less than the highest of (i) the closing price of HK\$3.55 per Share as stated in the Stock Exchange’s daily quotations sheet on the Date of Grant; (ii) the average closing price of HK\$3.56 per Share as stated in the Stock Exchange’s daily quotations sheets for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of HK\$0.10 per Share) |
| Number of Share Options granted | : | An aggregate of 2,300,000 Share Options, each Share Option entitling the holder thereof to subscribe for one Share at the exercise price mentioned above |

Closing price of the Share : HK\$3.55 per Share
on the Date of Grant

Validity period of the Share : From the Date of Grant to 10 November 2021 (both dates
Options granted inclusive)

Exercise periods of the : Each Grantee is entitled to exercise the Share Options in
Share Options accordance with the following vesting periods and in the following
manner:

- (a) up to 20% of the total number of Share Options granted to such Grantee is exercisable during the period from 11 May 2017 to 10 November 2021 (both dates inclusive);
- (b) up to 20% of the total number of Share Options granted to such Grantee is exercisable during the period from 11 November 2017 to 10 November 2021 (both dates inclusive);
- (c) up to 20% of the total number of Share Options granted to such Grantee is exercisable during the period from 11 May 2018 to 10 November 2021 (both dates inclusive);
- (d) up to 20% of the total number of Share Options granted to such Grantee is exercisable during the period from 11 November 2018 to 10 November 2021 (both dates inclusive); and
- (e) up to 20% of the total number of Share Options granted to such Grantee is exercisable during the period from 11 May 2019 to 10 November 2021 (both dates inclusive).

All outstanding or unexercised Share Options granted to the Grantees shall lapse after 10 November 2021.

Among the Share Options granted to the Grantees, a total of 1,000,000 Share Options were granted, with the approval by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules, to Mr. Ngiam Hian Leng Malcolm, being an associate (as defined in the Listing Rules) of a Director and substantial shareholder of the Company.

Save as disclosed in this announcement, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or any of their respective associates.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 11 November 2016

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.